Metastatic Colorectal Cancer Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Metastatic Colorectal Cancer pipeline constitutes key companies continuously working towards developing Metastatic Colorectal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Metastatic Colorectal Cancer Overview
Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the rectm. These cancers can also be called colon cancer or rectal cancer, depending on where they start. CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC).

"Metastatic Colorectal Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Colorectal Cancer Market.

The Metastatic Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Metastatic Colorectal Cancer Pipeline Report: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Metastatic Colorectal Cancer treatment therapies with a considerable amount of success over the years. Metastatic Colorectal Cancer Key players such as - Plus Therapeutics, Processa Pharmaceutical, Shanghai Henlius Biotech, Genor Biopharma, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Sunshine Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Amgen, G1 Therapeutic s, Inc., and others, are developing therapies for the Metastatic Colorectal Cancer treatment
• Metastatic Colorectal Cancer Emerging therapies such as - 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept (ALX148), CPGJ 602, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Lumakras (sotorasib), Trilaciclib, and others are expected to have a significant impact on the Metastatic Colorectal Cancer market in the coming years.
• In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA
• In March 2022, ALX Oncology Inc. in collaboration with Merck Sharp & Dohme Corp. and Eli Lilly and Company will initiate a Phase II Study (With Safety run-in) of ALX148 in Combination with Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
• On November 18, 2021 Gilead Sciences announced that it had exercised its options to three of Arcus Biosciences' programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat. The two companies have also added a research collaboration deal. Arcus shares popped 15% at the news.
• In September 2021, Erasca, announced a clinical trial collaboration and supply agreement with Pfizer Inc. for the BRAF inhibitor encorafenib (BRAFTOVI®). This agreement will support a clinical proof-of-concept study evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E-mutant mCRC.
• In December 2021, Rottapharm Biotech announced a clinical collaboration with Agenus' balstilimab (anti-PD-1) in collaboration with its lead candidate CR6086 in advanced colorectal cancer at the National Cancer Institute. Rottapharm Biotech's clinical collaboration with Agenus offers a promising new combination therapy for patients with advanced pMMR/MSS mCRC where there is a high unmet need, and for a further range of potential applications in other immunotherapy-resistant tumors.
• On 11 May 2021, Shanghai Henlius Biotech and NeuPharma entered into a drug technology license agreement. NeuPharma will grant the Company a sublicensable exclusive license for related licensed patents and licensed know-how necessary or reasonably useful for the Company to research, develop, produce and commercialize the Licensed Product within the Licensed Territory (China).
• In November 2021, The US FDA granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC). This serves as a strong external validation of arfolitixorin's potential to benefit patients with this devastating disease.
• In October 2020, G1 Therapeutics initiated a Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
• In August 2020, G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, and Simcere Pharmaceutical Group, a pharmaceutical company rapidly transitioning to an innovative and R&D-driven company in China, announced an exclusive license agreement for the development and commercialization of trilaciclib across all indications in Greater China (mainland China, HongKong, Macau and Taiwan)

Route of Administration
Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment
• Metastatic Colorectal Cancer Assessment by Product Type
• Metastatic Colorectal Cancer By Stage and Product Type
• Metastatic Colorectal Cancer Assessment by Route of Administration
• Metastatic Colorectal Cancer By Stage and Route of Administration
• Metastatic Colorectal Cancer Assessment by Molecule Type
• Metastatic Colorectal Cancer by Stage and Molecule Type

DelveInsight's Metastatic Colorectal Cancer Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Metastatic Colorectal Cancer Therapeutics Market include:
Key companies developing therapies for Metastatic Colorectal Cancer are - Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others.

Emerging Metastatic Colorectal Cancer Drugs Under Different Phases of Clinical Development Include:
• 188RNL-BAM: Plus Therapeutics
• PCS11T: Processa Pharmaceutical
• HLX13: Shanghai Henlius Biotech
• Geptanolimab: Genor Biopharma
• HDM201: Novartis Pharmaceuticals
• TP-1454: Sumitomo Pharma Oncology
• NT219: Purple Biotech Ltd.
• NKTR-255: Nektar Therapeutics
• Evorpacept (ALX148): ALX Oncology Inc.
• CPGJ 602: Sunshine Guojian Pharmaceutical
• Trastuzumab deruxtecan: Daiichi Sankyo
• GRT-C901: Gritstone Bio, Inc.
• SHR-1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Lumakras (sotorasib): Amgen
• Trilaciclib: G1 Therapeutic s, Inc.

Get a Free Sample PDF Report to know more about Metastatic Colorectal Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Colorectal Cancer Pipeline Analysis:
The Metastatic Colorectal Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Colorectal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer Treatment.
• Metastatic Colorectal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Metastatic Colorectal Cancer product details are provided in the report. Download the Metastatic Colorectal Cancer pipeline report to learn more about the emerging Metastatic Colorectal Cancer therapies at:
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Colorectal Cancer Pipeline Market Drivers
• Emergence of targeted therapies for mCRC treatment
• Technical Advancement in molecular subtyping of CRC tumors
• Increase in product development activities

Metastatic Colorectal Cancer Pipeline Market Barriers
• Limitations in understanding secondary resistance
• Challenges related to precision oncology in mCRC management

Scope of Metastatic Colorectal Cancer Pipeline Drug Insight
• Coverage: Global
• Key Metastatic Colorectal Cancer Companies: Plus Therapeutics, Processa Pharmaceutical, Shanghai Henlius Biotech, Genor Biopharma, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Sunshine Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Amgen, G1 Therapeutic s, Inc., and others
• Key Metastatic Colorectal Cancer Therapies: 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept (ALX148), CPGJ 602, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Lumakras (sotorasib), Trilaciclib, and others
• Metastatic Colorectal Cancer Therapeutic Assessment: Metastatic Colorectal Cancer current marketed and Metastatic Colorectal Cancer emerging therapies
• Metastatic Colorectal Cancer Market Dynamics: Metastatic Colorectal Cancer market drivers and Metastatic Colorectal Cancer market barriers

Request for Sample PDF Report for Metastatic Colorectal Cancer Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Metastatic Colorectal Cancer Report Introduction
2 Metastatic Colorectal Cancer Executive Summary
3 Metastatic Colorectal Cancer Overview
4 Metastatic Colorectal Cancer- Analytical Perspective In-depth Commercial Assessment
5 Metastatic Colorectal Cancer Pipeline Therapeutics
6 Metastatic Colorectal Cancer Late Stage Products (Phase II/III)
7 Metastatic Colorectal Cancer Mid Stage Products (Phase II)
8 Metastatic Colorectal Cancer Early Stage Products (Phase I)
9 Metastatic Colorectal Cancer Preclinical Stage Products
10 Metastatic Colorectal Cancer Therapeutics Assessment
11 Metastatic Colorectal Cancer Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Metastatic Colorectal Cancer Key Companies
14 Metastatic Colorectal Cancer Key Products
15 Metastatic Colorectal Cancer Unmet Needs
16 Metastatic Colorectal Cancer Market Drivers and Barriers
17 Metastatic Colorectal Cancer Future Perspectives and Conclusion
18 Metastatic Colorectal Cancer Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Metastatic Colorectal Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Metastatic Colorectal Cancer Market https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Metastatic Colorectal Cancer-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Metastatic Colorectal Cancer Epidemiology https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Metastatic Colorectal Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.